A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Phase of Trial: Phase I/II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs PTR 01 (Primary)
- Indications Epidermolysis bullosa
- Focus Adverse reactions; First in man
- Sponsors Phoenix Tissue Repair
- 07 Nov 2019 According to a BridgeBio Pharma media release, topline data anticipated during 2020.
- 30 Apr 2019 According to a Phoenix Tissue Repair media release, the company has opened enrollment of the second cohort of this study.
- 22 Feb 2019 According to a Phoenix Tissue Repair media release, the company announced that the first patient has been dosed for this study.